Nonradiologists are receiving over half of Medicare payments for diagnostic radiology procedures.
Nonradiologists receive more than half of diagnostic radiology fees issued by Medicare, according to a study published in the American Journal of Roentgenology.
Researchers from Virginia, California, and Georgia studied regional variation in the Medicare Physician Fee Schedule (MPFS) payments for medical imaging made to radiologists compared with nonradiologists.
The researchers used a 5% random sample from approximately 2.5 million Part B beneficiaries of Medicare enrollees covered in 2011. Calculations were done of state-by-state spending and regional spending for all Medicare-covered medical imaging services. The researchers also identified payments to radiologists versus nonradiologists.
The results showed that, nationally, mean MPFS medical imaging spending per Medicare beneficiary was $207.17. Radiologists received an average of $95.71 and nonradiologists received an average of $111.46. “Of professional-only (typically interpretation) payments, 20.6 percent went to nonradiologists,” the researchers wrote. “Of technical-only (typically owned equipment) payments, 84.9 percent went to nonradiologists. Of global (both professional and technical) payments, 70.1% went to nonradiologists.”
The percentage of MPFS medical imaging varied geographically, with spending on nonradiologists ranging from 32% in Minnesota to 69.5% in South Carolina. “The percentage of MPFS payments for medical imaging to nonradiologists exceeded those to radiologists in 58.8% of states,” the researchers noted. The relative percentage of MPFS payments to nonradiologists was highest in the South at 58.5%, and lowest in the Northeast, at 48.0%.
In breaking down what areas of imaging were reimbursed, the researchers found that of the $111.46 per beneficiary paid to nonradiologists, most ($46.62) went to cardiology, followed by internal medicine ($9.57), and orthopedic surgery ($7.43).
Specific modalities billed most commonly by radiologists were:
• CT: 73,373,949; 30.4%
• MRI: 65,923,094; 27.3%
• Radiography: 62,181,501; 25.8%
• Ultrasound: 24,025,296; 10.0%
• Nuclear medicine: 11,360,303; 4.7%
Specific modalities billed most commonly by nonradiologists were:
• Ultrasound: 111,589,763; 39.7%
• Nuclear medicine: 62,497,071; 22.2%
• Radiography: 57,123,644; 20.3%
• CT: 16,399,497; 6.51%
• MRI: 14,672,477; 5.2%
The researchers concluded that 53.8% of MPFS payments for medical imaging services are made to nonradiologists, who claim a majority of MPFS payments in most states dominated by noninterpretive payments.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.